Key result
Adjunctive CFAE or LALA ablation provides no arrhythmia-free survival benefit over PVI alone.
Why the study?
Does adjunctive CFAE ablation or LALA improve arrhythmia-free survival compared to PVI alone in patients with persistent atrial fibrillation?
Meta-Analysis (n=1,821)
Does adjunctive CFAE ablation or LALA improve arrhythmia-free survival compared to PVI alone in patients with persistent atrial fibrillation?
Effect estimate: RR 0.86 (CFAE) / RR 0.64 (LALA) (95% CI 0.64-1.16 (CFAE) / 0.37-1.09 (LALA))
p-value: p=0.32 (CFAE) / 0.10 (LALA)
In persistent AF, adding CFAE or linear ablation to PVI does not improve arrhythmia-free survival but increases procedural times.
No takes yet. Share an insight, caveat, or question.
Adjunctive CFAE or LALA should not accompany PVI in persistent AF; confirms no arrhythmia-free survival benefit.
Scott et al. (2015) conducted a meta-analysis in Persistent atrial fibrillation (PsAF) (n=1,821). Adjunctive complex fractionated atrial electrogram (CFAE) ablation or left atrial linear ablation (LALA) vs. Pulmonary vein isolation (PVI) alone was evaluated on Arrhythmia-free survival (RR 0.86 (CFAE) / RR 0.64 (LALA), 95% CI 0.64-1.16 (CFAE) / 0.37-1.09 (LALA), p=0.32 (CFAE) / 0.10 (LALA)). Adjunctive CFAE ablation (RR 0.86; 95% CI 0.64-1.16; P=0.32) or LALA (RR 0.64; 95% CI 0.37-1.09; P=0.10) offered no significant improvement in arrhythmia-free survival compared to PVI alone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: